FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291214487> ?p ?o ?g. }

• W4291214487 endingPage "1285" @default.
• W4291214487 startingPage "1267" @default.
• W4291214487 abstract "A recent phase 3, randomized, placebo- and tramadol-controlled trial (56-week treatment/24-week safety follow-up) demonstrated efficacy of tanezumab 10 mg in patients with chronic low back pain (CLBP) and a history of inadequate response to standard-of-care analgesics. Here, we report on the clinical meaningfulness of treatment response in this study, focused on secondary measures of pain, interference with daily functions, overall disease status, and satisfaction with treatment.Patients received placebo (up to week 16; n = 406), subcutaneously administered (SC) tanezumab 5 mg (every 8 weeks; n = 407), SC tanezumab 10 mg (every 8 weeks; n = 407), or orally administered tramadol prolonged-release (100-300 mg/day; n = 605) for 56 weeks. Patient's global assessment of low back pain (PGA-LBP), Brief Pain Inventory-short form (BPI-sf), Treatment Satisfaction Questionnaire for Medication (TSQM), and modified Patient-Reported Treatment Impact (mPRTI) were assessed at weeks 16 and 56.At week 16, significant (p < 0.05) improvements over placebo were evident with tanezumab for the PGA-LBP (10 mg) and most BPI-sf (both doses), TSQM (both doses), and mPRTI (both doses) items assessed. Improvements over baseline persisted for the PGA-LBP and BPI-sf at week 56. However, the magnitude of improvements was modestly lower at week 56 relative to week 16. Tramadol did not improve PGA-LBP or BPI-sf scores versus placebo at week 16. Most differences between tanezumab and tramadol at week 56 did not reach the level of statistical significance for all endpoints.The totality of the evidence as captured by measures of pain, interference with daily function, patient overall assessment of disease status, and satisfaction with treatment demonstrates the clinically meaningful benefit of tanezumab for some patients with CLBP compared with placebo.gov: NCT02528253." @default.
• W4291214487 created "2022-08-13" @default.
• W4291214487 creator A5004367944 @default.
• W4291214487 creator A5009534806 @default.
• W4291214487 creator A5011530088 @default.
• W4291214487 creator A5039668849 @default.
• W4291214487 creator A5043138248 @default.
• W4291214487 creator A5064599465 @default.
• W4291214487 creator A5070602040 @default.
• W4291214487 creator A5084258579 @default.
• W4291214487 creator A5089760100 @default.
• W4291214487 creator A5090431664 @default.
• W4291214487 date "2022-08-13" @default.
• W4291214487 modified "2023-09-30" @default.
• W4291214487 title "Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial" @default.
• W4291214487 cites W1820077142 @default.
• W4291214487 cites W1974337338 @default.
• W4291214487 cites W1994174812 @default.
• W4291214487 cites W1998172740 @default.
• W4291214487 cites W2006059711 @default.
• W4291214487 cites W2023370307 @default.
• W4291214487 cites W2060302340 @default.
• W4291214487 cites W2081338578 @default.
• W4291214487 cites W2087455247 @default.
• W4291214487 cites W2105674995 @default.
• W4291214487 cites W2121393149 @default.
• W4291214487 cites W2150324393 @default.
• W4291214487 cites W2154693681 @default.
• W4291214487 cites W2327575756 @default.
• W4291214487 cites W2468136237 @default.
• W4291214487 cites W2526359197 @default.
• W4291214487 cites W2540497002 @default.
• W4291214487 cites W2588410069 @default.
• W4291214487 cites W2592844790 @default.
• W4291214487 cites W2743046890 @default.
• W4291214487 cites W2791379829 @default.
• W4291214487 cites W2898512959 @default.
• W4291214487 cites W2948001442 @default.
• W4291214487 cites W2954490590 @default.
• W4291214487 cites W2971440260 @default.
• W4291214487 cites W2981147601 @default.
• W4291214487 cites W3004608962 @default.
• W4291214487 cites W3014194256 @default.
• W4291214487 cites W3027130245 @default.
• W4291214487 cites W3027729271 @default.
• W4291214487 doi "https://doi.org/10.1007/s40122-022-00424-7" @default.
• W4291214487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35962939" @default.
• W4291214487 hasPublicationYear "2022" @default.
• W4291214487 type Work @default.
• W4291214487 citedByCount "1" @default.
• W4291214487 countsByYear W42912144872023 @default.
• W4291214487 crossrefType "journal-article" @default.
• W4291214487 hasAuthorship W4291214487A5004367944 @default.
• W4291214487 hasAuthorship W4291214487A5009534806 @default.
• W4291214487 hasAuthorship W4291214487A5011530088 @default.
• W4291214487 hasAuthorship W4291214487A5039668849 @default.
• W4291214487 hasAuthorship W4291214487A5043138248 @default.
• W4291214487 hasAuthorship W4291214487A5064599465 @default.
• W4291214487 hasAuthorship W4291214487A5070602040 @default.
• W4291214487 hasAuthorship W4291214487A5084258579 @default.
• W4291214487 hasAuthorship W4291214487A5089760100 @default.
• W4291214487 hasAuthorship W4291214487A5090431664 @default.
• W4291214487 hasBestOaLocation W42912144871 @default.
• W4291214487 hasConcept C126322002 @default.
• W4291214487 hasConcept C142724271 @default.
• W4291214487 hasConcept C1862650 @default.
• W4291214487 hasConcept C204787440 @default.
• W4291214487 hasConcept C27081682 @default.
• W4291214487 hasConcept C2779777798 @default.
• W4291214487 hasConcept C2780052408 @default.
• W4291214487 hasConcept C2780820201 @default.
• W4291214487 hasConcept C2780907711 @default.
• W4291214487 hasConcept C2781118164 @default.
• W4291214487 hasConcept C42219234 @default.
• W4291214487 hasConcept C535046627 @default.
• W4291214487 hasConcept C71924100 @default.
• W4291214487 hasConceptScore W4291214487C126322002 @default.
• W4291214487 hasConceptScore W4291214487C142724271 @default.
• W4291214487 hasConceptScore W4291214487C1862650 @default.
• W4291214487 hasConceptScore W4291214487C204787440 @default.
• W4291214487 hasConceptScore W4291214487C27081682 @default.
• W4291214487 hasConceptScore W4291214487C2779777798 @default.
• W4291214487 hasConceptScore W4291214487C2780052408 @default.
• W4291214487 hasConceptScore W4291214487C2780820201 @default.
• W4291214487 hasConceptScore W4291214487C2780907711 @default.
• W4291214487 hasConceptScore W4291214487C2781118164 @default.
• W4291214487 hasConceptScore W4291214487C42219234 @default.
• W4291214487 hasConceptScore W4291214487C535046627 @default.
• W4291214487 hasConceptScore W4291214487C71924100 @default.
• W4291214487 hasFunder F4320307758 @default.
• W4291214487 hasFunder F4320307765 @default.
• W4291214487 hasIssue "4" @default.
• W4291214487 hasLocation W42912144871 @default.
• W4291214487 hasLocation W42912144872 @default.
• W4291214487 hasLocation W42912144873 @default.
• W4291214487 hasOpenAccess W4291214487 @default.
• W4291214487 hasPrimaryLocation W42912144871 @default.
• W4291214487 hasRelatedWork W1972824835 @default.

• next